Literature DB >> 27914122

Design, Synthesis, and Structure-Activity Relationships of Bavachinin Analogues as Peroxisome Proliferator-Activated Receptor γ Agonists.

Guoxin Du1, Yuanyuan Zhao1, Li Feng1, Zhuo Yang2, Jiye Shi3, Cheng Huang1, Bo Li2, Fujiang Guo1, Weiliang Zhu2, Yiming Li1.   

Abstract

Peroxisome proliferator-activated receptor γ (PPARγ) agonists have been used for the treatment of diabetes with the effect of lowering blood glucose levels and improving insulin sensitivity. Natural compounds such as flavones, flavanones, and isoflavones have shown excellent PPARγ agonist activity. In this study, analogues of bavachinin were designed, synthesized, and evaluated by reporter gene assays for PPARγ agonist activity. Preliminary structure-activity relationships for these bavachinin analogues have been summarized, and seven compounds were found to have higher PPARγ agonist activities than the parent flavanone bavachinin.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  PPARγ; bavachinin; diabetes mellitus; reporter gene assays; structure-activity relationships

Mesh:

Substances:

Year:  2016        PMID: 27914122     DOI: 10.1002/cmdc.201600554

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.540


  4 in total

1.  A bavachinin analog, D36, induces cell death by targeting both autophagy and apoptosis pathway in acute myeloid leukemia cells.

Authors:  Wen Zhang; Jingwen Liu; Yiming Li; Fujiang Guo
Journal:  Cancer Chemother Pharmacol       Date:  2022-08-12       Impact factor: 3.288

2.  Induction of G2/M Cell Cycle Arrest via p38/p21Waf1/Cip1-Dependent Signaling Pathway Activation by Bavachinin in Non-Small-Cell Lung Cancer Cells.

Authors:  Jih-Tung Pai; Ming-Wei Hsu; Yann-Lii Leu; Kuo-Ting Chang; Meng-Shih Weng
Journal:  Molecules       Date:  2021-08-25       Impact factor: 4.927

3.  Bavachinin exhibits antitumor activity against non‑small cell lung cancer by targeting PPARγ.

Authors:  Lu-Na Ge; Lei Yan; Cheng Li; Kai Cheng
Journal:  Mol Med Rep       Date:  2019-07-11       Impact factor: 3.423

4.  Study on the 2-Phenylchroman-4-One Derivatives and their anti-MERS-CoV Activities.

Authors:  Ji Hye Yoon; Jihye Lee; Jun Young Lee; Young Sup Shin; Dong Eon Kim; Jung Sun Min; Chul Min Park; Jong Hwan Song; Seungtaek Kim; Sunoh Kwon; Min Seong Jang; Hyoung Rae Kim
Journal:  Bull Korean Chem Soc       Date:  2019-07-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.